Bal Pharma

Bal Pharma Operating Cash Flow

The Operating Cash Flow of Bal Pharma (BALPHARMA.NS) as of Nov 2, 2026 is 144.72 M INR. In the previous year, Operating Cash Flow was 42.32 M INR — a change of 241.95% (higher).

Operating Cash Flow

144.72 MINR

YoY

241.95%

Last updated:

Operating Cash Flow of Bal Pharma is 2026 144.72 M INR. Operating Cash Flow of Bal Pharma was 2025 42.32 M INR. It decreases by 241.95% higher compared to the previous year.

The Bal Pharma Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2019
77.58 M INR
Jan 1, 2020
231.01 M INR
Jan 1, 2021
217.81 M INR
Jan 1, 2022
277.08 M INR
Jan 1, 2023
-18.44 M INR
Jan 1, 2024
228.06 M INR
Jan 1, 2025
42.32 M INR
Jan 1, 2026
144.72 M INR
The Bal Pharma Operating Cash Flow history
YEAROperating Cash FlowYoY
144.72 MINR+241.95%
42.32 MINR-81.44%
228.06 MINR-1,337.09%
-18.44 MINR-106.65%
277.08 MINR+27.21%
217.81 MINR-5.71%
231.01 MINR+197.79%
77.58 MINR-1,664.03%
-4.96 MINR-108.47%
58.58 MINR-130.27%
-193.53 MINR-233.17%
145.33 MINR+9.16%
133.13 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bal Pharma Stock analysis

What does Bal Pharma do? Bal Pharma Ltd. generates revenue through the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company specializes in bulk actives, prescription drugs, generics, and pharma intermediates, targeting therapeutic areas such as anti-diabetes, anti-histamine, anti-inflammatory, acne treatment, gastroenterology, cardiology, and dermatology. Its product portfolio includes APIs like antihistamine, platelet inhibitor, anti-diabetic, and anti-inflammatory agents, alongside finished formulations in tablets, capsules, syrups, and ointments. Key brands such as ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP are marketed to healthcare providers and consumers in these therapeutic segments. The company sells its APIs to other pharmaceutical manufacturers for further processing into finished products, while its finished formulations are distributed to hospitals, pharmacies, and clinics. Brands like AYURFINE and MENOLEAP CAPSULES target specific patient groups, such as those requiring anti-inflammatory or menopause treatment, respectively. The natural medicine line, including AYURSULIN and PROLIFE, caters to consumers seeking alternative treatments in diabetes and reproductive health. Revenue is derived from both B2B sales of APIs and direct B2C or B2B2C sales of branded formulations across multiple therapeutic categories. Bal Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bal Pharma stock

Operating Cash Flow of Bal Pharma is 144.72 M INR in 2026.

Operating Cash Flow of Bal Pharma changed from 42.32 M INR to 144.72 M INR, representing a 241.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Bal Pharma since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Bal Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bal Pharma

All Key Metrics — Bal Pharma